Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38(10 Suppl 3):S158–S168

Article  PubMed  Google Scholar 

Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–1500

Article  CAS  PubMed  Google Scholar 

Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015;62:1893–1908

Article  PubMed  Google Scholar 

Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–S165

Article  CAS  PubMed  Google Scholar 

Gonzalez SA, Perrillo RP. Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis. 2016;62(Suppl 4):S306–S313

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian–Pacific Association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–390

Article  PubMed  Google Scholar 

Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309

Article  PubMed  Google Scholar 

Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–1749

Article  CAS  PubMed  Google Scholar 

Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–244

Article  PubMed  Google Scholar 

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken). 2018;12:33–34

Article  PubMed  Google Scholar 

Xu Z, Dai W, Wu YT, et al. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: a meta-analysis. Eur J Cancer Care (Engl). 2018;27(2): e12799

Article  CAS  PubMed  Google Scholar 

Liu Z, Jiang L, Liang G, et al. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: a review and meta-analysis of prophylaxis management. J Viral Hepat. 2017;24(7):561–572

Article  CAS  PubMed  Google Scholar 

Liao YJ, Li YC, Lee SW, et al. Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up. J Chin Med Assoc. 2017;80(12):758–765

Article  PubMed  Google Scholar 

Cai Q, Chen K, Chen J, et al. The effect of prophylactic lamivudine plus adefovir therapy compared with lamivudine alone in preventing hepatitis B reactivation in lymphoma patients with high baseline HBV DNA during chemotherapy. PLoS ONE. 2016;11(10): e0164210

Article  PubMed  PubMed Central  Google Scholar 

EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017:370–398

Google Scholar 

Buti M, Manzano ML, Morillas RM, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. PLoS ONE. 2017;12: e0184550

Article  PubMed  PubMed Central  Google Scholar 

Zhang MY, Zhu GQ, Shi KQ, et al. Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7:30642–30658

Article  PubMed  PubMed Central  Google Scholar 

Chen MH, Chou CT, Hou MC, Tsai CY, Huang YH. Low but long-lasting risk of reversal of seroconversion in patients with rheumatoid arthritis receiving immunosuppressive therapy. Clin Gastroenterol Hepatol. 2020;18:2573-2581.e1

Article  CAS  PubMed  Google Scholar 

Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104(3):435–443

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seto WK, Chan TSY, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–3743

Article  CAS  PubMed  Google Scholar 

Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38:3698–3715

Article  CAS  PubMed  Google Scholar 

European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398

Article  Google Scholar 

Charlton MR, Alam A, Shukla A, et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020;55:811–823

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toka B, Koksal AS, Eminler AT, et al. Comparison of tenofovir disoproxil fumarate and entecavir in the prophylaxis of HBV reactivation. Dig Dis Sci. 2021;66(7):2417–2426

Article  CAS  PubMed  Google Scholar 

Suda G, Baba M, Yamamoto Y, et al. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis. J Med Virol. 2023;95(2): e28452

Article  CAS  PubMed  Google Scholar 

Zhao Y, Song Y, Zhang H, et al. Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: a network meta-analysis. Front Oncol. 2023;12:1050714

Article  PubMed  PubMed Central  Google Scholar 

Ma Y, Yang L, Bao Y, et al. Case Report: Post-CAR-T infusion HBV reactivation in two lymphoma patients despite entecavir preventive therapy. Front Immunol. 2021;12: 751754

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao W, Wei J, Wang N, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T cell therapy. Blood. 2020;136(4):516–519

Article  PubMed  Google Scholar 

Inada K, Kaneko S, Kurosaki M, et al. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open. 2021;5(9):1085–1091

Article  PubMed  PubMed Central  Google Scholar 

Sarin SK, Kumar M, Lau GK, et al. Asian–Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98

Article  CAS  PubMed  Google Scholar 

Lee IC, Chao Y, Li C-P, et al. Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy. J Viral Hepat. 2018;25:1599–1607

Article  CAS  PubMed  Google Scholar 

Jung CY, Kim HW, Ahn SH, Kim SU, Kim BS. Tenofovir is associated with higher risk of kidney function decline than entecavir in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2022;20(4):956-958.e2

Article  CAS  PubMed  Google Scholar 

Lee MJ, Hsu HJ, Wu IW, Sun CY, Ting MK, Lee CC. Vitamin D deficiency in northern Taiwan: a community-based cohort study. BMC Public Health. 2019;19(1):337

Article  PubMed  PubMed Central  Google Scholar 

Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55–59

Article  CAS  PubMed  Google Scholar 

Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33:167–177

Article  CAS  PubMed  Google Scholar